A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Saved in:
| Title: | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. |
|---|---|
| Authors: | Dotan E; Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. efrat.dotan@fccc.edu, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ |
| Source: | Journal of gastrointestinal cancer [J Gastrointest Cancer] 2012 Dec; Vol. 43 (4), pp. 562-9. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Print Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
